Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 56

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 56
---
 filing fees, printing expenses and other related fees and expenses. Many of these expenses will be payable by us regardless of
whether the Divestiture is completed.

Further, pursuant to the terms of the Divestiture Agreement, between the date of the Divestiture Agreement and the
date of the completion of the Divestiture, and thereafter following the date of the closing of the Divestiture, Aadi and Kaken must negotiate in good faith and use reasonable best efforts to enter into and execute the Transition Services Agreement,
on such terms as may be mutually agreed by Aadi and Kaken. The Transition Services Agreement will provide that from and after the closing of the Divestiture, Aadi will make available to Kaken for a period of not less than three months but not more
than six months following the date of the closing of the Divestiture, such services and resources (including the time of certain of its executive management and employees) that in each case Aadi has access to and are within Aadi’s control, as
Kaken may reasonably require in order to be able to conduct and operate the FYARRO Business following the closing of the Divestiture in substantially the same or a similar manner as the manner in which it was operated prior to the completion of the
Divestiture. Performance of our obligations under the Transition Services Agreement will incur significant financial costs and the focus and attention of our management and employee resources may be diverted from our remaining business and ADC
Programs.

Our executive officers and directors may have interests in the Divestiture other than, or in addition to, the interests of our stockholders generally.

Members of our board of directors and our executive officers may have interests in the Divestiture that are different
from, or are in addition to, the interests of our stockholders generally. Our board of directors was aware of these interests and considered them, among other matters, in approving the Divestiture Agreement. Additional information on these interests
can be found in the section entitled “The Divestiture Agreement—Interests of Aadi’s Directors and Executive Officers in the Divestiture” beginning on page [●] of this proxy statement.

Lawsuits may be filed against Aadi challenging the Divestiture and an adverse ruling in any such lawsuit may prevent the Divestiture from being completed at all or from being completed within the expected time frame.

One of the conditions to the completion of the Divestiture is the absence
of any judgment or law issued or enacted by any governmental